Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Vascular Diseases 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma 1Lymphatic Diseases 1Immunoproliferative Disorders 1Hemorrhagic Disorders 1Hematologic Diseases 1Cardiovascular Diseases 1Blood Protein Disorders 1

Interventions

Bortezomib 4fludarabine 3Lenalidomide 3dacetuzumab 2Tacrolimus 2Dexamethasone 2Alemtuzumab 2plerixafor 1ofatumumab 1isatuximab 1fludarabine phosphate 1ficlatuzumab 1epratuzumab 1Whole-Body Irradiation 1Vorinostat 1Stem Cell Transplantation 1Rifaximin 1Mycophenolic Acid 1KW-2478 1Hsp90 inhibitor KU757 1Granulocyte Colony-Stimulating Factor 1Erlotinib Hydrochloride 1Cyclophosphamide 1Clonal Hematopoiesis 1Chromatin Immunoprecipitation Sequencing 1Calcium Dobesilate 1CLR1404 1Busulfan 1Blood Cell Count 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraproteinemias × ficlatuzumab × Lymphoid × Clear all
NCT00725634 2014-01-27

P05538

AVEO Pharmaceuticals, Inc.

Phase 1 Completed
41 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡